Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Updated on: October 06,2025 0

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Updated on:October 06,2025 0

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

Updated on: October 05,2025 0

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

Updated on:October 05,2025 0

Is multicancer testing valuable? Questions to ask before getting screened

Updated on: October 05,2025 0

Is multicancer testing valuable? Questions to ask before getting screened

Updated on:October 05,2025 0

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Updated on: October 05,2025 0

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Updated on:October 05,2025 0

Repurposing a diabetes medication to prime CAR T cancer targets

Updated on: October 05,2025 0

Repurposing a diabetes medication to prime CAR T cancer targets

Updated on:October 05,2025 0

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Updated on: October 05,2025 0

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Updated on:October 05,2025 0

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Updated on: October 05,2025 0

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Updated on:October 05,2025 0

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Updated on: October 05,2025 0

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Updated on:October 05,2025 0

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on: October 05,2025 0

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on:October 05,2025 0

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on: October 05,2025 0

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on:October 05,2025 0